

Rare Diseases Forum 1

Wednesday, October 17, 2018

Carnegie Endowment for International Peace
Participant List

Qais Abu Ali, MD

Medical Director
Ultragenyx Pharmaceutical

Nicholas Ah Mew, MD

Director, Inherited Metabolic Disorders
Program
Children's National

Stephen Aselage

Chief Executive Officer
Retrophin

Abigail Barth

Associate Public Policy & Special Projects
Amicus Therapeutics

Annetta Beauregard, MBA, MS

Vice President, Regulatory Policy &
Operations
Vertex Pharmaceuticals

Jennifer Bernstein, MA

Executive Vice President
Horizon Government Affairs

Susan Berry, MD

Professor of Pediatrics
University of Minnesota

Melanie Blank, MD

Medical Officer
U.S. Food and Drug Administration

Tara Britt

Associate Chair
NC Rare Disease Advisory Council, UNC
Medicine

P.J. Brooks, PhD

Program Director, Office of Rare Diseases Research
National Center for Advancing Translational
Sciences, National Institutes of Health

Barry Byrne, MD, PhD

Director, Powell Center for Rare Disease
Research & Therapy
University of Florida

Michelle Campbell, PhD

Reviewer and Scientific Coordinator
U.S. Food and Drug Administration

Lisa Carlton, MS, PhD

Senior Director, Regulatory Affairs
REGENXBIO Inc.

Wen-Hung Chen, PhD*

Lead Clinical Analyst
U.S. Food and Drug Administration

Yeh-Fong Chen, PhD

Mathematical Statistician, Team Lead
U.S. Food and Drug Administration

John F. Crowley, JD, MBA

Chairman and CEO
Amicus Therapeutics

Althea Cuff, MS

Science Policy Analyst
U.S. Food and Drug Administration

Terry Daniels, MPH

Administrative Officer
Forum for Collaborative Research

Mark Dant

Chair, Board of Directors
EveryLife Foundation for Rare Diseases

Ebony Dashiell-Aje, PhD

Social Scientist, Clinical Outcome
Assessments Reviewer
U.S. Food and Drug Administration

* Denotes remote participation

Aaron Davis, MA

Chief Executive Officer
Tavistock Group

Ellie Dehoney, MPH

Vice President, Policy and Advocacy
Research!America

Jenny Doan, MSN, BSN*

Regulatory Project Manager
U.S. Food and Drug Administration

Kathleen Donohue, MD

Lead Medical Officer
U.S. Food and Drug Administration

Monique Fleck

Regulatory Affairs Manager
Amicus Therapeutics

Margie Frazier, PhD, MSW

Immediate Past Executive Director
Batten Disease Support and Research
Association

Danielle Friend, PhD

Director, Science and Regulatory Affairs
Biotechnology Innovation Organization

Beth Frigola-McGinn

Co-Founder, Executive Director
A Cure for Ellie

Ilan Ganot, MBA

Founder, CEO, President
Solid Biosciences

Lili Garrard, PhD*

Mathematical Statistician
U.S. Food and Drug Administration

Jayne Gershkowitz

Chief Patient Advocate
Amicus Therapeutics

Nancy Goodman, JD

Executive Director
Kids V Cancer

Katherine Greene, MPH

Senior Research Associate
Forum for Collaborative Research

Elizabeth Hart, MD

Medical Officer
U.S. Food and Drug Administration

Luis Javier Hernandez

Project Manager
Forum for Collaborative Research

Christine Hon, PharmD

Pharmacologist
U.S. Food and Drug Administration

Sophia Hufnagel, MD*

Medical Officer, Pediatric Geneticist
U.S. Food and Drug Administration

Ilan Irony, MD

Deputy Division Director
U.S. Food and Drug Administration

Dave Jacoby, MD, PhD

Fellow, VP, Head of Clinical Science
BioMarin Pharmaceutical

Dilara Jappar, PhD

Clinical Pharmacologist
U.S. Food and Drug Administration

Linda Jeng, MD, PhD*

Medical Officer
U.S. Food and Drug Administration

Julia Jenkins

Executive Director
EveryLife Foundation for Rare Diseases

Devanand Jillapalli, MD

Medical Officer
U.S. Food and Drug Administration

Laura Lee Johnson, PhD

Director, Division Of Biometrics III
U.S. Food and Drug Administration

Amel Karaa, MD

Assistant Professor & Director, Mitochondrial
and Lysosomal Storage Disorders
Harvard Medical School & Massachusetts
General Hospital

* Denotes remote participation

Sean Kassen, PhD

Director, Ara Parseghian Medical Research Fund
University of Notre Dame

Lucas Kempf, MD

Acting Associate Director, Rare Diseases
Program
U.S. Food and Drug Administration

Vivian Kessler, RAC

Executive Director, Global Regulatory Affairs
Amicus Therapeutics

Sharon King, BA

President
North Carolina Rare Disease Coalition & Taylor's Tumor Forum for Collaborative Research

Priya Kishnani, MD*

Professor of Pediatrics & Division Chief for
Medical Genetics
Duke University Medical Center

Genevieve Laforet, MD, PhD

Senior Director, Clinical R&D
Solid Biosciences

Josh Lehrer, MD

Senior Vice President
Global Blood Therapeutics

Sandra Lehrman, MD

Independent Consultant & Patient Advocate

Harvey Levy, MD*

Senior Physician, Medicine/Genetics
Boston Children's Hospital & Harvard
Medical School

Caroline Loewy

Co-Founder & Board Member
KCNQ2 Cure Alliance

Nicola Longo, MD, PhD*

Professor And Chief, Medical Genetics
University of Utah

Erica Lyons, MD

Medical Officer
U.S. Food and Drug Administration

Erin MacLeod, PhD, RD

Director, Metabolic Nutrition
Children's National Rare Disease Institute

Jeffrey Marrasso, MPA, MBA

Chief Executive Officer
Spark Therapeutics

Scott McGoohan, JD

Director, US Regulatory Policy &
Intelligence
Vertex Pharmaceuticals

Veronica Miller, PhD

Executive Director

Ken Mills, SB

President & CEO
REGENXBIO Inc.

Min Min, PhD*

Mathematical Statistician
U.S. Food and Drug Administration

Christine Mueller, DO

Medical Officer
U.S. Food and Drug Administration

Andrew Mulberg, MD

Vice President Global Regulatory Affairs
Amicus Therapeutics

Lily (Yeruk) Mulugeta, PharmD

Clinical Reviewer,
U.S. Food and Drug Administration

Adora Ndu, PharmD, JD

Executive Director, Regulatory Affairs
BioMarin Pharmaceutical

Mary Newman, MS

Senior Vice President, Regulatory Affairs
Audentes Therapeutics

Susan Nichols

Chief Executive Officer
Falcon Therapeutics

Bindi Nikhar, MD

Acting Deputy Division Director
U.S. Food and Drug Administration

* Denotes remote participation

Stephanie Omokaro, MD

Lead Medical Officer
U.S. Food and Drug Administration

Nancy Parsons, MSc

Vice President, Leadiant Biosciences

Jackye Peretz, PhD

Toxicologist
U.S. Food and Drug Administration

Forbes Porter, MD, PhD

Senior Investigator And Clinical Director
National Center for Advancing Translational
Sciences, National Institutes of Health

Mark Pykett, VMD, PhD*

Chief Innovation Officer
PTC Therapeutics

Jorge Quiroz, MD, MBA

Chief Medical Officer
Solid Biosciences

Brenda Rodriguez, MBA, MSc

Development Manager
Forum for Collaborative Research

Dragos Roman, MD

Medical Officer
U.S. Food and Drug Administration

Frank Sasinowski, MS, MPH, JD

Director
Hyman, Phelps & McNamara, P.C.

Bruce Schneider, MD

Medical Officer, Team Leader
U.S. Food and Drug Administration

Robert Schuck, PharmD, PhD

Clinical Pharmacologist
U.S. Food and Drug Administration

Shirley Seo, PhD

Division Director, Division of Clinical Pharmacology
U.S. Food and Drug Administration

Jeffrey Sherman, MD, FACP

Chief Medical Officer and Executive Vice President
Horizon Pharma, Inc

Patroula Smpokou, MD

Lead Medical Officer
U.S. Food and Drug Administration

Donna Snyder, MD

Senior Pediatric Ethicist
U.S. Food and Drug Administration

Lisa Soule, MD

Associate Director, DGIEP
U.S. Food and Drug Administration

Scott J. Steele, Ph.D.

Director, Regulatory Science Programs
Clinical and Translational Science Institute
Associate Professor, University of Rochester

Kristin Stephenson, MHA, JD

Sr. VP, Chief Policy & Community
Engagement Officer
Muscular Dystrophy Association

Marshall L. Summar, MD

Chief of Genetics and Metabolism &
Director, Rare Disease Institute
Children's National Medical Center

Pranoot Tanpaiboon, MD

Associate Medical Director, Advanced
Diagnostics Genetics, Genomics and R&D,
Biochemical Genetics, Quest Diagnostics

Cynthia Tifft, MD, PhD

Director, Pediatric Undiagnosed Diseases
Program, National Human Genome
Research Institute, NIH

Bruce Turner, MD, PhD

Managing Director
Tavistock Group

Julienne, Vaillancourt. RPh, MPH

Rare Diseases Liaison
U.S. Food and Drug Administration

Tracy VanHoutan

President
Noah's Hope Foundation - Batten Disease

Jerry Vockley, MD, PhD

Chief Medical Genetics
University of Pittsburgh

* Denotes remote participation

Hong Vu, PharmD, MS, GWCPM*

Regulatory Project Manager
U.S. Food and Drug Administration

Heidi L. Wagner, J.D.

SVP, Government Affairs & Policy
Global Blood Therapeutics

Jie (Jack) Wang, PhD

Lead Pharmacologist
U.S. Food and Drug Administration

Ron Wange, PhD

Associate Director for Pharmacology & Toxicology
U.S. Food and Drug Administration

Jessica Weber, BSN, MSc

Senior Research Associate
Forum for Collaborative Research

Holly Weng, MD, MHS

Executive Medical Director
BioMarin Pharmaceutical

David Whiteman, MD

Global Development Lead, Rare Metabolic
Diseases, R&D
Shire Pharmaceuticals

Chester Whitley, PhD, MD

Professor, College of Pharmacy
University of Minnesota

David Williams, MBA

President
Health Business Group

Matt Wilsey, MBA

President & Chief Executive Officer
Grace Science Foundation

Rachel Witten, MD

Medical Officer
U.S. Food and Drug Administration

Janet Woodcock, MD

Director, Center for Drug Evaluation & Research
U.S. Food and Drug Administration

Dina Zand, MD

Medical Officer
U.S. Food and Drug Administration

* Denotes remote participation